$66.52
-1.73 (-2.53%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MBX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional
Held by 7 tracked-famous managers (MARSHALL WACE, LLP, Schonfeld Strategic Advisors LLC, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, +2 more) · FINRA short interest 8.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With HypoparathyroidismNCT07699471To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Canvuparatide · Other: Placebo | Hypoparathyroidism | 160 | Jan 2028 | ≤ 530 d | 2026-07-13 |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With HypoparathyroidismNCT06531941To evaluate the long-term safety and tolerability of weekly MBX 2109 in patients with hypoparathyroidism.Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | Hypoparathyroidism | 60 | 2027-05-27 | in 281 d | 2025-10-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With ObesityNCT07142707Number of participants with Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: MBX 4291, Placebo | Obesity | 124 | 2026-10-30 | in 72 d | 2026-06-09 |
| Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)NCT07029412Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416.Open-label · Treatment | Phase 2 | Completed | Drug: MBX 1416 (INN imapextide) | Postbariatric Hypoglycemia | 20 | 2026-04-18actual | — | 2026-07-02 |
| Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal FunctionNCT06496217Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)Open-label · Basic science | Phase 1 | Completed | Drug: MBX 2109, MBX 2109, MBX 2109, MBX 2109 | Renal Impairment | 25 | 2025-09-04actual | — | 2025-10-28 |
| Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismNCT06465108To evaluate the effect of pooled weekly doses of MBX 2109 on the proportion of responder patients defined by serum calcium levels and treatment with active vitamin D and calcium supplements at Week 12/Visit 15Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: MBX 2109 · Other: Placebo | Hypoparathyroidism | 64 | 2025-05-23actual | — | 2026-03-20 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsNCT06036784Number of participants with adverse events (AEs), Serious Adverse Events (SAEs)Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C) | Postbariatric Hypoglycemia | 69 | 2024-11-14actual | — | 2024-12-12 |
| Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult SubjectsNCT05158335Primary Outcome MeasuresRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: MBX 2109 (Part A), MBX 2109 (Part B), Placebo | Healthy | 76 | 2023-06-20actual | — | 2023-08-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19